Idexx Laboratories Inc (IDXX) Financial Statements
Historical financial data — 42 statements covering FY2016–FY2025
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline...
Idexx Laboratories Inc's revenue increased 10.4% year over year, from $3.90B to $4.30B.
Net income increased 19.3% over the same period, from $887.9M to $1.06B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 142% in total.
Total debt decreased by 16.7% to $374.8M.
The debt-to-equity ratio stands at 0.23, indicating a conservative leverage profile.
Operating cash flow grew 27.2% to $1.18B.
Idexx Laboratories Inc maintains a strong net profit margin of 24.6%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2024 | $975.5M-2.8% | $232.8M | $596.0M | $242.4M | $220.1M | $3.35B | $524.8M | $1.62B |
| Q4 FY2024 | $954.3M-2.2% | $216.1M | $570.7M | $261.7M | $262.0M | $3.29B | $449.8M | $1.60B |
| Q1 FY2025 | $998.4M+4.6% | $242.7M | $623.4M | $316.5M | $238.0M | $3.21B | $449.8M | $1.45B |
| Q2 FY2025 | $1.11B+11.1% | $294.0M | $694.7M | $373.0M | $185.7M | $3.33B | $449.8M | $1.46B |
| Q3 FY2025 | $1.11B-0.4% | $274.6M | $683.4M | $354.8M | $402.3M | $3.39B | $374.8M | $1.56B |
| Q4 FY2025 | $1.09B-1.3% | $248.2M | $658.1M | $315.6M | $355.8M | $3.35B | $374.8M | $1.61B |
| Q1 FY2026 | $1.14B+4.6% | $278.4M | $722.7M | $362.6M | $266.2M | $3.39B | $1.11B | $1.56B |
| Q2 FY2026 | $1.22B+6.6% | $338.4M | $779.1M | $425.6M | $347.2M | $3.44B | $1.10B | $1.61B |
Balance Sheet Summary (Q2 FY2026)
Idexx Laboratories Inc (IDXX) Financial Statements & Revenue History
Idexx Laboratories Inc (IDXX) is a US-listed stock operating in the Healthcare sector, specifically the In Vitro & In Vivo Diagnostic Substances industry trading at $560.36 with a market capitalization of $44. This page provides 42 historical financial statements for Idexx Laboratories Inc, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Idexx Laboratories Inc reported revenue of $4.3 billion, representing 10.4% year-over-year growth. The net profit margin of 24.6% reflects strong profitability. The debt-to-equity ratio of 0.23 shows conservative leverage.
IDXX Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Idexx Laboratories Inc's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether IDXX is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track IDXX's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Idexx Laboratories Inc converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of IDXX's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use IDXX Financial Data
Investors use Idexx Laboratories Inc's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare IDXX's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how IDXX's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View IDXX's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Idexx Laboratories Inc's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.IDXX trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.